Publicaciones

• —Lupera H, Pico JL, Moran A, Baume D, Beaujean F, Ostronoff M, Hayat M.
• —High toxicity associated with Busulfan and Ciclophosphamide with autologous BMT in the patients with advanced lymphoma.
• —Bone Marrow transplantation 1988;3(supp II):308.
• —Droz JP, Theodore C, Ghosn M, Lupera H, Piot G, De Forges A, Klink, Rousse J, Amiel JL.
• —Twelve years experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave Roussy.
• —Seminars in Surgical Oncology. 1988;4(2):97-99.
• —Thyss A, Hoffman P, Michiels JF, Thyss-Puyraimond F, Lupera H, Scheneider M.
• —Malignant lymphoma with centrofollicular cells associated with pseudomyelomatous lytic bone lesions
• —Rev Rhum Mal Osteoartic. 1987 Jul-Sep;54(7-9): 601-3
• —Droz JP, Lupera H, Ghosn M, Charrot P, Metz R, Fargeot P, Theodore C, Alain Y.
• —Phase II trial with Methotrexate (M), Vinblastine (V), Adriamicin (A), and Cisplatin (C). (MVAC regimen) in advanced stage bladder cancer.
• —In Steg A, Di Silverio F, Eds: International workshops in Urological- Proccedings. New trends in bladder cancer chemotherapy. Acta Urol Ital 1987; 1987, 8 (suppl 1).
• —Droz JP, Theodore C, Ghosn M, Azab M, Ostronoff M, Lupera H, Court BH, Perrin JL.
• —Current status of phase II trials of drugs in advanced urothelial tract cancer.
• —In Steg A, Di Silverio F, Eds: International workshops in Urology – Proccedings, New trends in bladder cancer chemotherapy. Acta Urol Ital 1987;8(suppl I).
• —Lupera H, Theodore C, Ghosn M, Court BH, Wibault P, Droz JP.
• —Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cancer.
• —Urology. 1989 Nov;34(5):281-3. doi: 10.1016/0090-4295(89)90326-9.
• —Lupera H, Droz JP, Piot G, Lapleige P, Fargeot P, Theodore C.
• —Phase II trial of combination chemotherapy with Fluorouracil (F), doxorubicin (A), and cisplatin (FAP) in hormonally resistant metastatic prostatic adenocarcinoma.
• —Oncology. 1989;46(6):372-4. Doi: 10.1159/000226753.
• —Lupera H, Droz JP, Culine S, Perrin JL, Court BH, Ghosn M, Hayat M.
• —Cancer of the bladder after treatment with cyclophosphamide. A propos of a case and a review of the literature.
• —J Urol (Paris). 1990;96(1):48-52.
• —Culine S, Azab M, Pietri F, Ghosn M, Ben Amor B, Lupera H, Theodore C, Renaux J, Droz JP.
• —A phase II trial comparing the antiemetic activity of tetracosactide with dexamethasone in combination with metoclopramide, diphenhydramine and clorazepate during chemotherapy including cisplatin.
• —Bull Cancer. 1989;76(6)589-9.
• —Arrieta O, Cardona AF, Bramuglia G, Cruz Rico G, Corrales L, Martin C, Imaz-Olguin V, Castillo O, Cuello M, Rojas-Bilbao E, Casas G, Fernadez C, Aren Frontera O, Denninghoff V, Recondo G, Aviles -Saalas A,Mas-Lopes LA, Oblitas G, Rojas L,
• —Piottante A, Jimenez-Garcia E, Sanchez-Sosa S, Saenz-Frias J, Lupera H, Ramirez-Tirado LA, Vargas C, Carranza H, Astudillo H, Wills LB, Pichelbaur E, Raez LE; on behalf of the CLICaP.
• —Oncology. 2019;96(4): 207-216. Doi: 10.1159/000493733. Epub 2018 Nov 26.
• —Lupera H.- Rol emergente de Gemcitabina (Gemzar) en el tratamiento del cancer de mama en ASCO-2003.
• —American Journal of Clinical Oncology.
• —Cancer Clinical Trials. 2003;13-16.
• —Lupera H. As co investigator of the GEICAM group.
• —Gemcitabine plus vinorelvine vs vinorelvine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of a phase III Spanish Breast Cancer Research Group (GEICAM) trial.
• —The Lancet Oncology 2007; 219-225.
• —Salvatierra EH, Noboa AP, Lupera H, Teran F, Troconis E, Colmenter L.
• —Parameters of the 18 F-FDG PET/CT associated with prognostic factors in the initial staging of Breast Cancer.
• —Rev.Oncol.Ecu 2019;29(2):97-109.
• —Lupera H.
• —Cancer y embarazo. In Jijon A,Sacoto M, Cordova A. Alto riesgo obstetrico.
• —2006;461-469
• —Lupera H.
• —Los elementos genéticos que gobiernanel cancer: Protooncogenos y Antioncogenos. Revista Ecuatoriana de Cancerologia. 1988;16-18
• —Lupera H.
• —Comunicación intracelular. Revista Ecuatoriana de Cancerologia. 1988;22-23
• —Lupera H
• —Terapia Genica Humana. Revista Ecuatoriana de Cancerologia. 1988;22-23
• —Colmenter L, Troconis JE, Cornejo F, Boboa A, Ramos O, Lupera H.
• —Metabolismo of the prostate and progression to prostate cancer. Revista Virtual de Radiologia. 2018;9(3)
• —Lupera H
• —Linfoma de Hodgkin en adultos
• —Guia de practica clínica. 2017;MSP. Ecuador
• —Colmenter L, Torres M, Zuñiga S, Carmona A, Bernal L, Vilar J, Palomino Javier, Teran F, Lupera H, Marti A, Novoa A.
• —Inmunoterapia y sus cambios en las imágenes multimodales 18 FDG-PET/CT.
• —Rev Venez Oncol 2024;36(3):192-207
• —Colmenter L, Troconis MD, Cornejo F, Noboa A, Ramos O, Lupera H.
• —Application of positrón emisión tomography in prostate cancer marked with 68Ga-PSMA: Review and update.
• —Federacion Ecuatoriana de Radiologia e imagen 2018;11(1):13-20
• —Colmenter L, Torres M, Zuñiga Sergio, Bernal L, León M, Lupera H, Terán F, Vilar J, Bowles H.
• —Inteligencia Artificial en PET/CT y PET/RM en Oncología: Los cuatro escenarios.
• —Rev Venez Oncol: 2025;37(1):5-15